Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Generation 2 Dual GLP-1/GIP Agonists (Tirzepatide) Tirzepatide was the first dual-agonist incretin peptide to reach advanced clinical research
Calculate your units: Verify the concentration on your vial label
.png)
Robust, randomised, placebo-controlled human trials are essentially absent for both peptides
Per Trimi's published Refund Policy (last updated June 17, 2026): you need to stay on a continuous paid plan for six full months, take the medication as directed, log both a starting weight and a 6-month weight in the patient portal, and complete provider check-ins
Early data indicates retatrutide may outperform tirzepatide in diabetic kidney disease and weight loss
US$ 24.51
US$ 20.68
US$ 26.46
US$ 27.31
US$ 23.02
US$ 29.28
US$ 28.42
US$ 26.79
